While the combination of dabrafenib and trametinib is recommended in the treatment of BRAF V600E-mutated NSCLC in the main guidelines, in the event of the appearance of a BRAFV600E mutation as a resistance mechanism after osimertinib progression, there is currently disagreement over the best course of action for concurrently addressing BRAF and EGFR in lung cancer. Here, EGFR is linked to lung carcinoma.